⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMNM News
Immunome, Inc.
Form 8-K
sec.gov
IMNM
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
businesswire.com
IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
IMNM
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
businesswire.com
IMNM
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
businesswire.com
IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
IMNM
Form 8-K
sec.gov
IMNM
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
businesswire.com
IMNM